Key Insights

Highlights

Success Rate

88% trial completion (above average)

Published Results

34 trials with published results (18%)

Research Maturity

92 completed trials (48% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

6.3%

12 terminated out of 192 trials

Success Rate

88.5%

+1.9% vs benchmark

Late-Stage Pipeline

18%

34 trials in Phase 3/4

Results Transparency

37%

34 of 92 completed with results

Key Signals

34 with results88% success12 terminated

Data Visualizations

Phase Distribution

146Total
Not Applicable (64)
Early P 1 (1)
P 1 (10)
P 2 (37)
P 3 (23)
P 4 (11)

Trial Status

Completed92
Recruiting28
Unknown25
Terminated12
Active Not Recruiting11
Not Yet Recruiting8

Trial Success Rate

88.5%

Benchmark: 86.6%

Based on 92 completed trials

Clinical Trials (192)

Showing 20 of 20 trials
NCT07453602Phase 1Recruiting

Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234

NCT07011706Phase 2Active Not Recruiting

ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis

NCT07846813Not Yet RecruitingPrimary

Evidencing Vibroacoustic Sensing for Inflammatory Skin Disease Monitoring

NCT01631617Phase 2RecruitingPrimary

Effects of Treatments on Atopic Dermatitis

NCT06702293Not ApplicableRecruitingPrimary

Use of a Digital Psychotherapeutic App to Reduce Symptom Burden in Dermatology Patients

NCT06807268Phase 3RecruitingPrimary

A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

NCT04031469Suspended

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

NCT00605878RecruitingPrimary

Studies of Skin Microbes in Healthy People and in People With Skin Conditions

NCT07447063Phase 4RecruitingPrimary

The Impact of Dietary Salt on the Severity of Eczema

NCT07746427Not ApplicableRecruiting

Digital Mindfulness Meditation in Adolescents With Atopic Dermatitis

NCT07355075Phase 2Recruiting

A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)

NCT07599813Phase 2Recruiting

A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

NCT06353087Completed

Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry)

NCT06096857Phase 2Recruiting

Cardamom and Topical Roseomonas in Atopic Dermatitis

NCT07037901Phase 2Recruiting

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

NCT07228962RecruitingPrimary

Cutaneous Biomarkers in Atopic Eczema Using a Non-Invasive Micro-Suction Device in Babies

NCT06994520Phase 2Enrolling By Invitation

Efficacy of Topical Cannabidiol for Eczema

NCT07463079Not ApplicableCompletedPrimary

Clinical Evaluation of a Soothing Moisturizing Lotion in Individuals With Atopic Eczema

NCT05735483Phase 3Enrolling By Invitation

A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

NCT05559359Phase 3Active Not Recruiting

A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Scroll to load more

Research Network

Activity Timeline